UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015891
Receipt number R000017676
Scientific Title Study to evaluate the clinical effectiveness of intermittent infusion hemodiafiltration (I-HDF)
Date of disclosure of the study information 2014/12/10
Last modified on 2017/04/27 13:26:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study to evaluate the clinical effectiveness of intermittent infusion hemodiafiltration (I-HDF)

Acronym

Study to evaluate the clinical effectiveness of I-HDF

Scientific Title

Study to evaluate the clinical effectiveness of intermittent infusion hemodiafiltration (I-HDF)

Scientific Title:Acronym

Study to evaluate the clinical effectiveness of I-HDF

Region

Japan


Condition

Condition

Chronic Kidney Failure

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the clinical condition and quality of life (QOL) of I-HDF compared with HD.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

SF-36 ver2
Clinical condition (VAS scale)

Key secondary outcomes

Vital signs (blood pressure, pulse)
Number of treatments by medical staff
Blood test
Dose of erythropoietin-stimulating agent
Solute removal ability


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment Maneuver

Interventions/Control_1

HD therapy (for 3 months) --> I-HDF therapy (for 3 months) --> HD therapy (for 3 months)

Interventions/Control_2

I-HDF therapy (for 3 months) --> HD therapy (for 3 months) --> I-HDF therapy (for 3 months)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Hemodialysis patient who on-line HDF therapy is possible, and can give written informed consent
- 18 years and over
- Hemodialysis for more than 6 months

Key exclusion criteria

1) Patients with severe cardiovascular disease (NYHA class 3 or 4), hepatic failure, respiratory failure, or malignant tumor
2) 8% or more of the rate of weight gain
3) Patients who are judged ineligible by the attending physician.

Target sample size

70


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Michio Mineshima

Organization

Tokyo Women's Medical University

Division name

Department of Clinical Engineering

Zip code


Address

8-1, Kawada-cho, Shinjuku-ku, Tokyo

TEL

03-3353-8111

Email

mmine@twmu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ryoichi Sakiyama

Organization

Tokyo Women's Medical University

Division name

Department of Clinical Engineering

Zip code


Address

8-1, Kawada-cho, Shinjuku-ku, Tokyo

TEL

03-3353-8111

Homepage URL


Email

sakiyama@twmu.ac.jp


Sponsor or person

Institute

I-HDF Multicenter Study Group

Institute

Department

Personal name



Funding Source

Organization

JMS Co., Ltd.
Asahi Kasei Medical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

常磐病院(福島県)
名港共立クリニック(愛知県)
偕行会城西病院(愛知県)
偕行会セントラルクリニック(愛知県)
鴨島川島クリニック(徳島県)
鳴門川島クリニック(徳島県)
中島土谷クリニック(広島県)
大町土谷クリニック(広島県)
新古賀クリニック(福岡県)
古賀病院21(福岡県)
伊都クリニック(福岡県)
たかみや医院(熊本県)


Other administrative information

Date of disclosure of the study information

2014 Year 12 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 06 Month 24 Day

Date of IRB


Anticipated trial start date

2014 Year 09 Month 18 Day

Last follow-up date

2014 Year 11 Month 30 Day

Date of closure to data entry

2015 Year 10 Month 01 Day

Date trial data considered complete

2016 Year 06 Month 30 Day

Date analysis concluded

2017 Year 04 Month 27 Day


Other

Other related information



Management information

Registered date

2014 Year 12 Month 10 Day

Last modified on

2017 Year 04 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017676


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name